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PENKLONAN DAN PENGEKSPRESAN CYP2D6*1 DAN CYP2D6*10 
SERTA APLIKASINYA DALAM: KAJIAN IN VITRO INTERAKSI UBAT-
HERBAL 
AKSTRAK 
CYP2D6 mempakan salah satu enzim CYP utama dania bertanggungjawab 
dalam metabolisma kira-kira 20% daripada ubat-ubatan yang terdapat pada masa 
kini. CY2D6 adalah berpolymorfisma dan CYP2D6* 10 mempakan alelle kebiasaan 
di kalangan populasi Malaysia. Dat1. berkenaan interaksi herbal tempatan-ubatan 
adalah kekurangan. Objektif penyelidikan ini adalah menghasilkan assei in vitro 
berkenaan interaski ubatan-herbal dan mengunakannya untuk menganalisasi interaksi 
herbal tempatan. CYP2D6*1 rekombinan telah dihas ilkan dan diekpreskan bersama 
CYP-reductase dalam bacteria E. coli. CYP2D6* 10 dihasilkan dengan kaedah "site-
directed mutagenesis" dan diekpreskan sebagai CYP2D6* 1. Kaedah HPLC telah 
dibangunkan untuk mengukur aktivitii bufuralol 1 ' -hydroxylase dari CYP2D6. Dari 
segi pengukuran kinetik, Km dan Vmax bagi CYP2D6*1 mempakan 9.686 ± 0.674 
J..LM untuk 6.867 ± 0.119 pmoVminlpmol CYP2D6* 1. Manakala , Km dan Vmax 
CYP2D6*10 adalah 41.02 ± 0.674 J..LM dan 0.351 ± 0.0013 pmol/min!pmol 
CYP2D6* 10. Parameter kinetik untuk analisis aktiviti catalistik CYP2D6 secara in 
vitro adalah bersamaan dengan kajian-kajian terbitan lain. Ekstrak daripada tongkat 
ali (ELJ) menghalang CYP2D6*1 melalui mekanisme tidak kompetitif dan Ki serta 
IC50 masing-masing adalah 302.03 ± 10.59 ng/ml dan 178.38 ± 12.29 ng/ml. Namun 
EU menghalang CYP2D6*10 untuk tahap yang lebih rendah melalui mekanisme 
yang kompetitif dengan Ki sebanyak 215.29 ± 11.76 ng/ml dan IC50 adalah 490.90 ± 
13.88 ng/ml. ELJ tidak menunjukkan jenis penyekatan mekanisme. Perjumpaan ini 
XXl 
juga menunjukkan adanya interaksi ubat-herbal dan interaksi ubat-makanan ketika 
produk te1tentu dimakan bersama-sama dengan ubat-ubatan konvensional. 
Penyelidikan ini telah berjaya mengelkpresikan rekombinan protein CYP2D6* 1 dan 
CYP2D6* 10. Kaedah HPLC yang s.pesifik dan sensitif telah dikembangkan dan 
divalidasikan lmtuk analisis aktiviti in-vitro enzim katalitik dan kesan penyekatan 
EU. Penyelidikan selanjutnya diperlULkan untuk menyiasat kesan penyekatan herbal 
tempatan lain-lain atas kegiatan CYP2D6 untuk peningkatan pemahaman interaksi 
ubat-herbal. 
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CLONING AND EXPRESSION OF CYP2D6*1 AND CYP2D6*10 AND ITS 
APPLICATION IN IN VITRO DRUG-HERBS INTERACTION STUDIES 
AJBSTRACT 
CYP2D6 is one of the maJor CYPs enzymes and is responsible for the 
metabolism of about 20% of cunently available therapeutic chugs. CYP2D6 is 
polymorphic and CYP2D6* 10 is the common allele in the Malaysian population. 
There is lack of data on local herbal-drug interaction. The objective of this study was 
to generate an in vitro drug-herbs int1eraction assay and use it to analyse local herb 
interaction. Recombinant CYP2D6* 1 was generated and co-expressed with CYP-
reductase in E. coli. Recombinant CYP2D6*10 was generated using site-directed 
mutagenesis and expressed as CYP2D6* 1. The HPLC method was developed to 
measure bufuralol 1 '-hydroxylase activity of CYP2D6. The kinetic parameters, Km 
and Vmax for CYP2D6*1 were 9.686::1:: 0.674 JlM and 6.867 ± 0.119 pmoVminlpmol 
of CYP2D6*1 respectively. For CYP2D6*10, the Km and Vmax were 41.02 ± 0.674 
JlM and 0.351 ± 0.0013 pmoVmint!pmol of CYP2D6*10 respectively. Kinetic 
parameters from in vitro CYP2D6 catalytic activity analysis were in accordance with 
others published studies. Extracts of EU inhibited CYP2D6* 1 by non-competitive 
mechanism with Ki and IC50 of 302.03 ± 10.59 ng/ml and 178.38 ± 12.29 ng/ml, 
respectively. However EU inhibited CYP2D6* 10 to a lesser extent by competitive 
mechanism with Ki of215.29 ± 11.76 ng/ml and IC50 was 490.90 ± 13.88 ng/ml. ELJ 
did not show any mechanism-based inhibition. It also suggested the presence of 
chug-herb and chug-food interactions when certain natural products were consumed 
concunently with conventional medi,cines. This study have successfully expressed 
recombinant CYP2D6*1 and CYP2D6*10 protein. A specific and sensitive HPLC 
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method was developed and validated to analysis the in vitro catalytic activity of 
enzymes and ELJ inhibition effect. Future studies are required to investigate the 
inhibitmy effects of more local herbs on CYP2D6 activity for an improved 
lmderstanding of dmg-herb interactions. 
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1 INTRODUCTION AND REVIEW OF THE LITERATURE 
1.1 Introduction 
fudividual variations in response to chugs are a substantial clinical problem. 
fu nmmal clinical practice, the same dmg dosage is prescribed to different patients 
with the same disease without knowing their genetic backgrounds. Genetically 
detetmined variability in chug response defmes the research area known as 
phatmacogenetics (Wolf et al., 2000). Many chugs are metabolized by genetically 
polymorphic dmg-metabolizing enzymes (DMEs), distributed and eliminated by 
genetically polymorphic chug transporters (fugelman-Sundberg et al., 1999). For 
activity, the dmg needs to bind to another important genetically polymorphic protein, 
the receptor. 
Cytochrome P450 (CYP) comprises a supetfamily of haem-containing DMEs 
which catalyse the biotransfmmation of endogenous and foreign substances. This 
superfamily is divided into families and further subdivided into subfamilies 
according to their amino acid sequenees (Nelson et al. , 1996). Families are defmed 
as having more than 40% homology in their amino acid sequence and are designated 
by an Arabic numeral, and subfamilies have more than 55% analogy and are 
designated by a capital letter. An Arabic numeral after the letter denotes the 
individual enzyme and the gene associated with the enzyme is denoted in italics 
(Slaughter and Edwards, 1995). CYP2 is the largest family and among the member, 
CYP2D6 is of particular interest because it responsible for the metabolism of about 
20-25% of currently available dmgs including cardiovascular dmgs, ~-ach·energic 
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blocking agents, tricyclic antidepressants, analgesics and compounds such as 
methoxyamphetamine and dextromethmphan (Kroemer and Eichelbaum, 1995, 
fugelman-Sundberg, 2005, fugelman-Sundberg et al., 2007). fu addition, this enzyme 
is also genetically polymmphic leading to genetically polymmphic metabolism that 
can impact on medicine dosage (Desmeules et al., 1991, Edeki et al., 1995, Thuerauf 
and Lunkenheimer, 2006, Cascorbi, 2003, Gardiner and Begg, 2006). 
1.2 Literature Review 
1.2.1 Pharmacogenetics and Phannacogenomics 
An individual's response to medicine is dependent on factors that can be 
divided into physiological and environmental. Physiological factors include age, 
ethnicity, gender, body weight andl gene. On the other hand, dieta1y intake, 
concomitant dmg administration and exposure to chemicals are considered as 
environmental factors (Brazell et a!., 2002). Genetic variation is recognized as an 
important factor responsible for the variability in dmg response and this defmes the 
research area known as pha1macogenetics (Wolf et al., 2000). Pha1macogenetics was 
bom in the 1950s when researchers olbse1ved that some adverse dmg reactions were 
caused by genetic variations in enzyme activity (Meyer, 2000). fudividuals who 
inhe1it an enzyme deficiency and others who inherit enzyme abundance can benefit 
from phmmacogenetics with genetic tests (Koo and Lee, 2006) used to predict dose. 
Pha1macogenetics is the study of the genetic factors influencing variation in 
dmg metabolism and response (Palmer et a!., 2005). The completion of the human 
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genome project facilitated the study of variable dmg effects based on individual 
genetic make-up (Ma and Lu, 2011). The human genome project has identified 
numerous types of genetic variations among individuals that may or may not alter 
dmgs effects. The genetic variations are either classified as polymorphisms or 
mutations (Goodman eta!., 2011). A polymorphism is defmed as variation in a DNA 
sequence that occurs at a frequency ojf at least 1% in the human population, whereas 
a mutation occurs in less than 1 % (Wyatt et al., 2012). It results from single 
nucleotide polymorphisms (SNP), gene deletion or gene duplication at the same 
locus that encodes an enzyme or a protein that exists in the nmmal population 
(Nebert et al., 1996). Indeed SNP occurs throughout the human genome at a 
frequency of about 1 per 300-500 DNA base pair (Hinds et al., 2005, Reich et al., 
2003, Brazell et al., 2002). Individual fimctional variants caused by SNPs are 
associated with inter-individual and interethnic variation in dmg response (Koo and 
Lee, 2006). SNP mapping technology is a promising approach in pha1macogenetics. 
It enables the entire human genome to be intenogated to identify SNP profiles that 
are associated with medicine response. Previous approaches involved the 
identification a particular 'candidate gene' that influence dm g action (Brazell et al., 
2002). 
Cost effectiveness is a priority for healthcare providers and govemments 
(Brazell et a!., 2002). Pha1macogenetics has the potential to maximize the value of 
medicines. The rapid accumulation of knowledge on genome-disease and genome-
dmg interactions has also impelled the transfmmation of pha1macogenetics into a 
new entity of human genetics - phannacogenomics - and, at the same time, provided 
a rationale for the hope that individualized medicine can be achieved in the near 
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future (Ma and Lu, 2011). It will enable more infmmed prescribing decisions to be 
made so that patients receive treatments based on a predete1mined efficacy and 
safety profile (Brazell et al. , 2002). The ability to identify individuals who are 
exquisitely sensitive to medicine either before dmg treatment or after an adverse 
dmg response would also be of economic importance. It would avoid the empilicism 
associated with matching the most appropriate dmg at its optimal dose for each 
patient (Wolf et al., 2000). It may also substantially reduce the need for 
hospitalization with its associated costs, because of adverse dmg reactions (Wolf, 
2003). Phmmacogenetics is also able to provide infotmation about genetic 
characte1istics of a disease which could be used to improve dmg design and improve 
efficacy and safety of existing dmgs (Brazell et al., 2002). In future, 
phmm acogenetics may help in the dlete1mination of risk of disease based on the 
identification of susceptibility gene early in life so that measures can be taken to 
avoid the disease. Pha1macogeneties is especially impottant when the mugs 
prescribed have nanow therapeutic indexes and its metabolism polymorphic (Wolf et 
al., 2000). It is also important thatt when new dmgs are developed, relevant 
phmm acogenetic variations that can alter dmg disposition and/or pha1macodynamic 
are known early in the developmental stage so as to avoid unnecessa1y costs of dmg 
misadventures due to genetic traits (Wolf eta!., 2000). 
In dmg development, the identification of new mu g targets and the 
understanding of genetic factors that determine patient response to dmgs may allow 
the researchers venture into new paths in designing mu gs that are specifically 
targeted towards particular populations or that avoid genetic variability in therapeutic 
response. For example, polymorphism of the ~2 am·enoceptor gene has produced 
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responders and non responder pheno1types (Durham eta!. , 2004). This can lead to 
inconsistent results in the preclinical and clinical studies that would follow if such a 
dmg compound is pursued. Such targets can be avoided for dmg compounds. Thus, 
at an early stage, the targets can be clilaracterised based on pha1macogenetic studies 
combined with proteomics and suitable dmg compounds selected for fu1ther 
investment. The extent of genetic polymorphism in the human population indicates 
that pha1macogenetic variability will probably be an issue for most new dmgs (Wolf, 
2003). 
fu most cases, variation in dmg response in a disease is attributed to many 
genes rather than a single gene mutati[on. The results of pha1macogenetic studies do 
not apply when used clinically, as only single gene mutations are studied when in 
fact multiple genes are involved. lilt such cases, it would be appropriate to do 
phmmacogenomic studies comparing single nucleotide polymorphism (SNP) maps 
and gene expression between nmmal and affected individuals (Surendiran et al. , 
2008). This can identify the genetic factors associated with the disease and thus 
provide newer targets to characteriise and evaluate, for the purpose of dmg 
development. Those that could be potential future dmg targets can be called as 
"tractable" or "dmgable" targets (Mc:Ca1thy et a!., 2005). With the availability of 
advanced human genome sequences, the genes can now be analyzed in silica for 
coding regions of the tractable targets. Polymorphisms of P2Y 12 receptors in platelets 
have been identified to be associated with increased risk of corona1y arte1y disease 
by haplotype analysis (Cavallari et al., 2007). fu the future, this can be a potential 
target for a dmg compound produced against coronary arte1y disease. 
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1.2.2 Cytochrome P450 2D6 
The cytochrome P450 (CYP) superfamily represents the most important 
phase I dmg-metabolizing enzymes. They oxidize a large number of endogenous 
substances (e.g. eicosanoids and steroids) and xenobiotics (e.g. therapeutic dmgs and 
enviromnental compounds). The products from the these metabolism are usually 
more hydrophilic compounds that will facilitate elimination (Nebert and Russell, 
2002). There are as many as 57 functional CYP genes and 58 pseudogenes within the 
18 families (i.e. CYPs 1-5, 7, 8, 11, 17, 19-21, 24, 26, 27, 39, 46, and 51) in humans 
(http://dmelson.uthsc.edu/cytochromelP450.html). More than 90% of human dmg 
oxidation can be attributed to the following CYPs: 1A2 (4%), 2A6 (2%), 2C9 (10%), 
2Cl9 (2%), 2El (2%), 2D6 (30%) and 3A4 (50%) (Rendic, 2002). Genetic 
variability in CYP content and activihes can have a profound influence on the in vivo 
response of humans to dmgs. 
Genetic mutations indeed play an impo1tant role in the enzyme activity 
variations of many CYPs, in pat1icular CYP2A6, 2C9, 2Cl9 and 2D6 (Ingehnan-
Sundberg et a!., 2007). Genetic polymorphisms of CYPs mainly affect the 
metabolism of drugs that are their substrates, probably leading to the differences in 
dmg response and an altered risk for adverse dr11g effects (Ingehnan-Slmdberg et a!., 
2007, Kirchheiner and Seeringer, 2007, Tomalik-Scharte et al. , 2008, Zhou et al. , 
2009). Most members of 1the CYP families are polymorphic, 
(http://www.cypalleles.ki.se/cyp2d6.h1tm). Allelic variants resulting in altered protein 
expression or activity have significant effects on the disposition of drugs (Zhou, 
2009). 
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CYP2D6 has been one of the most intensively investigated CYPs in relation 
to genetic polymorphism. It however accounts for only a small percentage of the 
total hepatic CYPs content (2-4%). Nonetheless it metabolizes about 25% of 
cunently used dmgs in the human liver (Ingelman-Sundberg et al. , 2007, Cascorbi, 
2003, Gardiner and Begg, 2006, Ingelman-Sundberg, 2005, Zhou et al. , 2008). 
Typical substrates for CYP2D6 are: largely lipophilic bases and include some 
antidepressants, antipsychotics, antianhythmics, antiemetics, P-adrenoceptor 
antagonists (P-blockers) and opioids. Most CYP2D6 substrates are bases containing a 
basic nitrogen atom 5-10 A from the site of metabolism (Marechal et al., 2008). 
Cytochrome P450 2D6 appears to have a high affinity and a low capacity for its 
substrates. It becomes saturated at relatively low concentrations. 
The primarily hepatic expression of this enzyme govems first-pass 
metabolism after oral dmg administration. The low level of its intestinal expression 
does not appear to be important. In contrast to other CYPs, CYP2D6 is generally not 
regulated by many known environmental agents and is not inducible by common 
known enzyme inducers such as steroids (Bock et al., 1994). However CYP2D6 is 
subject to inhibition by a number of chugs, resulting in clinically significant chug 
interactions. 
1.2.3 Alleles of the CYP2D6 Gene 
CYP2D6 is highly polymorphic, to date, 74 allelic variants and a series of 
subvariants of the CYP2'D6 gene have been reported 
(http://www.cypalleles.ki.se/cyp2d6.h1tm). Its number of alleles is still increasing. 
Among these alleles, there are fully :flunctional alleles, alleles with reduced function 
and null (non-functional) alleles (Zhou et al., 2008, Zanger et al., 2004). Depending 
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on the specific CYP2D6 genotype, individuals can be divided into poor CYP2D6 
metabolizers (PM), inte1mediate CYP2D6 metabolizers (IM), extensive CYP2D6 
metabolizers (EM) or an ultrarapid CYP2D6 metabolizers (Daly, 2003). 
Null alleles of CYP2D6 are all des that do not encode a functional protein and 
there is no detectable residual enzymatic activity. Alleles *3, *4, *5, *6, *7, *8, *11, 
*12, *13, *14, *15, *16, *18, *19, *20, *21, *38, *40, *42, *44, *56 and *62 are null 
alleles and have no enzyme activity (Zhou, 2009). They are responsible for the poor 
metabolizer (PM) phenotype when present in homozygous or compound 
heterozygous constellations. These alleles are of clinical significance as they often 
cause altered dmg clearance and dmg response. 
Alleles CYP2D6*10, *14, *17, *18, *36, *41, *47, *49, *50, *51, *54, *55 
and *57 on the other hand give rise to a significantly decreased CYP2D6 activity. 
The reduced activity is often due to decreased protein stability, dismpted substrate 
recognition or reduced substrate-enzyme affinity. The enzyme activity change may 
be substrate-dependent for some alleles such as * 17. fudividuals harbouring either of 
these alleles are PMs or IMs. CYP2D6*10 occurs in 33-43% of Asians, including 
Malaysians, Japanese, Korean and Chinese, and in Pacific Islanders (Bradford, 2002, 
Ji eta!., 2002, Johansson eta!., 1994, Ishiguro eta!., 2004, Teh eta!., 2001). 
1.2.4 Substrates and Inhibitors of Human Cytochrome P450 (CYP) 2D6 
Apart from its genetic polymorphism, CYP2D6 is subject to environmental 
factors including inhibition by various dmgs, such as cimetidine and quinidine 
(Knodell eta!., 1991, Madeira eta!., 2004). Consequently, the extent of CYP2D6-
mediated dmg clearance may be inflluenced by other, co-administered therapeutic 
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agents. The competitive inhibition by quinidine is both potent, with a Ki of 3-30nM, 
and selective for CYP2D6. Quinidine is thus frequently used as an inhibitmy 
chemical probe for in vitro CYP2D6 enzyme kinetic study. Other probe chugs used 
as substrate for in vitro CYP2D6 enzyme kinetic study include debrisoquine ( 4-
hych·oxylation), dextromethorphan ( 0 -demethylation) and bufuralol (1 ' -
hych·oxylation). fu this study, bufuralol was used. The advantages of using bufuralol 
as a CYP2D6 selective substrate inclUtde the high sensitivity of the assay to study its 
kinetics owing to the highly fluorescent 1 '-hydroxybufuralol metabolite. It also 
avoids the use of radio-labelled substrate as is required by some other substrates. 
1.2.4.1 Bufuralol, the Substrate Probe 
Bufuralol is a non-cardioseleetive f3 -adrenoceptor antagonist (Fothergill et 
al., 1975). It possesses partial agonist activity at the f3 -ach·enoceptor (Hamilton and 
Parkes, 1977). Although, pa1t ial agolflist is of questionable therapeutic impmtance 
(McDevitt, 1983) bufuralol has been found to have vasodilator properties in man 
(Magometschnigg et al., 1978, Magometschnigg et al., 1979a, Magometschnigg et 
al., 1979b) and bronchodilator activity in animals (Blaber, 1982) which have been 
attributed to a ~-adrenoceptor agonist •effect. 
Bufuralol has been extensively used as a probe substrate for the in vitro study 
of CYP2D6 (Zanger et al. , 2004, Yuan et al., 2002). It is metabolized to three 
metabolites, namely 1 '-hydroxybufumlol, 1 ' -oxobufuralol, and 1 '2 '-ethenylbufuralol 
(Hiroi et a!. , 2002). The level of 1 ' -hydroxybufuralol, a major metabolite of 
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bufuralol, is often measured as an index of CYP2D6 activity and/or levels, and the 
amount of 1 ' -hydroxybufuralol fmmed from bufuralol is known to be small in PMs 
ofCYP2D6 (Carcillo et al., 2003). 
1.2.4.2 Quinidine, the Reversible Competitive Inhibitor 
Studies in the early 20th centmy identified quinidine, a diastereomer of the 
antimalarial quinine, as the most potent of the antiauhytlunic substances extracted 
from the cinchona plant, and by the 1920s, quinidine was used as an antiauhythmic 
agent. Quinidine is used to maintain sinus rhythm in patients with atrial flutter or 
atrial fibrillation and to prevent recurrence of ventricular tachycardia or ventricular 
fibrillation (Grace and Camm, 1998). Quinidine is not metabolized by CYP2D6 but 
has long been established as a potent competitive inhibitor of the enzyme (Branch et 
al. , 2000, Guengerich et al., 2002, Guengerich et al., 1986, Otton et al., 1988, von 
Bam· et al. , 1985). 
1.2.4.3 Paroxetine, Irreversible Mechanism Based Inhibitor 
Paroxetine is a selective serotonin reuptake inhibitor with nonlinear kinetics 
that is both a substrate for and an inhibitor of CYP2D6 (Belpaire et al. , 1998, 
Bloomer et al., 1992, Greenblatt et al. , 1999, Otton et al., 1996, Sindmp et al. , 1992a, 
Sindmp et al., 1992b). Paroxetine is metabolized by CYP2D6 via demethylenation of 
the methylenedioxy group, yielding a catechol metabolite and fomlic acid (Bloomer 
et al., 1992, Haddock et al., 1989). Paroxetine inhibits CYP2D6 activity at ICso 
concentrations ranging from 150 nM to 2.0 J.!M, depending on the substrate (Crewe 
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et al., 1992, von Moltke et al. , 1995, Fogelman et al. , 1999). Paroxetine has been 
shown to be a mechanism-based inhibitor of CYP2D6 (Bertelsen et al., 2003). 
1.2.5 Eurycoma longifolia, Jack 
Tongkat Ali is a popular medicinal plant in Malaysia. There is four different 
species of the Tongkat Ali plant, namely Eurycoma longifolia, Eurycoma apiculata, 
Polyathia bulata and Goniothala, mus sp (Aziz et al., 2003). Eurycoma longifolia is 
the most commonly used species (Athimulam et a!., 2006). Its belongs to 
Simaroubacea family (Shafiqul Islam et a!., 2006) and is indigenous to Southeast 
Asia, in the lowland forests of up to 500 m above sea level (Kuo et a!., 2003). It 
grows as a single-stemmed slow growing tree in the rainforest (Rahman et al., 2004) 
jungle slopes in Malaysia. This plant bears fmit after 2 Y2 years of cultivation while 
the root is usually taken to be processed after 4 years of cultivation. 
Eurycoma longifolia is known as 'Pasak Bumi' in Indonesia, 'Cay ba binh' in 
Vietnam and ' Ian-don' in Thailand. It is popularly sought after as an herbal remedy 
and is frequently prescribed either as a single ingredient preparation or as a mixture 
with other herbs (Kuo et a!., 2003). In Malaysia it is also known as Payung Ali, 
Penawar Pahit, Setunjang Bumi, Bedara Pahit, Tongkat Baginda, Pokok Syurga, 
Tongkat Ali Hitam, Pokok Jelas and Jelaih (Athimulam et al., 2006). Its most 
popular name however is 'Tongkat Alii'. 
Tongkat Ali is a popular folk medicine for the treatment of many diseases. It 
is used throughout the region as essential components in herbal medicines for a 
variety of illnesses such as aches, persistent fever, te1tient malaria, sex insufficiency 
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and granular swelling (Kuo eta!., 2003) and also as a health supplement. Tongkat 
Ali has been repmted to also possess: antimalarial, antiulcer, anti-pyretic, cytotoxic 
and aphrodisiac prope1ties (Rahman et al. , 2004). The nomadic aborigines (Orang 
Asli) in Malaysia consume Eurycoma longifolia, Jack daily when they have febrifuge 
and malaria (Ang et al. , 1995). Nowadays, extracts of Tongkat Ali is popular in 
commercial drinks and in tonics such as Tongkat Ali Power Root, Long Jack 
Tongkat Ali and many others. These drinks are marketed as being effective to restore 
energy and to increase sexual qualities. for men. 
The most popularly used part of Tongkat Ali is the root. Root extracts of 
Tongkat Ali contain quassinoids (Chan et al., 2004) such as emycomanone, 14, 15 ~­
dihydroxyklaineanone, emycomanol and emycomalactones (Shafiqul Islam et al., 
2006) giving it a bitter taste (Ang eta/'., 2002). 
1.2.6 In vitro Drug Interaction Study Models 
The selection of conect human models is necessary for the study and 
characte1ization of dmg metabolism (Masimirembwa et al., 1999). In vivo animal 
studies are both time-consuming and expensive and will not necessa1ily yield 
metabolic or phrumacokinetic information similar to that obtained in humans 
(Masimirembwa et al. , 1999). Ethical issue is another factor that needs to be 
considered when dealing with in vivo animal studies. Indeed human models are now 
widely accepted and utilized (Masimirembwa et al., 1999). Researches on enzyme 
kinetics in in vitro systems with CYPs have been extensively reported, acting as 
human models (Ekins et al., 1997). The following details some of the in vitro models 
applied to metabolism and how their use have been changing as we begin to 
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understand the enzymes and underlying cellular processes involved (Ekins et al., 
2000). 
1.2.6.1 Recombinant Enzymes 
Advances in molecular biology have opened the path to the stable expression 
of catalytically active CYPs in a variety of expression systems including bacteria 
(Wate1man, 1993), yeast (Oeda et al. , 1985), insects (Buters et al. , 1994) and 
mammalian cells (Crespi and Penman, 1997). These allowing the study of enzyme 
function and structure, leading to a gr1eater understanding of the individual isofmms. 
Additionally site directed mutagenesis and expression of these mutants for in vitro 
investigation has become a powerful tool in providing useful information with 
regards to subsn·ate-enzyme interactions (Domanski et al., 1999). 
Recombinant CYPs are also useful in high-throughput screemng assays, 
isofmm-selective metabolism, metabolite fmmation as well as in small scale 
bioreactors to generate useable amount of metabolic product (Friedberg eta!., 1999). 
Isolated heterogenous human CYP enzymes, expressed as single enzyme 
from complimentary DNA (eDNA) for in vitro models are commercially available. 
The availability of so many CYPs can be directly related to the initial isolation and 
reconstitution of CYP and its enzymatic cofactor, cytochrome P450 reductase (Lu 
and Coon, 1968). By the early 1990s, over 100 different CYPs have been cloned and 
sequenced, including the major human CYP isofmms (Nebert et al., 1991). 
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1.2.6.2 Subcellular Fractions 
Subcellular fractions which include microsomes, other cellular organelles and 
liver homogenates continue to be the most widely used in vitro system for dmg 
metabolism. Microsomes however remain the most widely used subcellular fraction 
(Ekins et a!., 2000). Fmthetmore, liver homogenates also contain all phase I and 
phase II dmg metabolizing enzymes (Ekins eta!., 2000). 
The advantages of subcellular fractions are that they are easy to prepare, are 
reproducible, are capable for lomg tetm storage and can provide ample 
charactetization of optimal incubation conditions (Ekins and Wrighton, 1999). Their 
disadvantages include the loss of somce enzyme activity during preparation. However 
this can be satisfactorily recreated by the addition of appropriate cofactors. Liver 
homogenates fmtified with appropriate cofactors exhibit the same enzyme activities 
as intact tissues do (Pelkonen et a!., 2005). Fresh tissues which are properly handled 
and frozen immediately after excision, are shown to have stable enzymatic activities 
even during prolonged storage (Pearce et al., 1996). 
1.2.6.3 Hepatocytes 
Hepatocytes contain the full complement of both phase I and phase II dmg 
metabolizing enzymes. They are therefore valuable tools for multiple uses including 
for metabolite identification, for transpmtation studies, and for the elucidation of 
possible toxic effects of dmgs (Holme, 1985). Good in vitro-in vivo correlations in 
the metabolic activity of a number of dmgs have been demonstrated and 
consequently, cultured human hepatoc:ytes are currently the most recommended tools 
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to study CYP-mediated metabolism and induction (Guillouzo et a!. , 1993). 
Widespread use of p1imary hepatocytes is however limited by the limited availability 
of liver tissues. Hepatocyte cultures can be prepared from whole livers and surgical 
wedge biopsies. The maintenance of nmmal cellular physiology and intercellular 
contacts in hepatocytes requires special matrix configurations demanding technical 
capabiliies (Kohira and Nakamura, 19:89). 
Although several c1yopreservation applications have been developed, the time for 
efficient use of a single hepatocyte batch is still quite short (Cross and Bayliss, 
2000); (Ekins et a!., 2000). The use of hepatocytes was also briefly challenged by 
precision-cut liver slices but interest on hepatocytes rose again as hepatocytes 
techniques such as sandwich culture (FeiTini et a!., 1997) and gel immobilized 
hepatocytes (Guyomard et al. , 1996) became available. 
1.2.6.4 Liver Slices 
Precision-cut liver slices close:ly resemble the liver at the organ level. They 
possess a wide range of enzymatic activities there are suitable for enzyme 
characte1isation. Liver slices are also suitable for induction studies (Edwards eta!. , 
2003). The system is moreover a valuable tool when whole cell metabolism needs to 
be studied in a short pe1iod (Ekins et al., 2000). 
Liver slices system became popular with the development of a slicer which 
was capable of producing slices of consistent dimensions with minimal cellular 
trauma (Kmmdieck eta!., 1980). This allows for the incubation of the liver or other 
tissue slices for many hours with appropriate oxygen and nutrient conditions 
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(Vickers et a!. , 1995). The time f01r use and to prepare a single slice is sh011; 
however, cryopreservation methods have overcome some of these problems (Ekins et 
al., 1996). Many studies have however shown lower cellular uptake, clearance, and 
metabolic capacity ofliver slices compared to hepatocytes (Worboys et al. , 1996). 
1.2.7 Mechanism of Inhibition of CYP 
Two major mechanisms are responsible for cytochrome P450 mediated dmg 
interactions: induction and potent inhibition. Induction refers to increased synthesis 
or decreased degradation of Cytochrome P450 enzymes. Induction promotes enzyme 
activity. Induction results in decreased plasma concentrations of the substrate. This 
can either cause a decrease or increase in its pha1macodynamic effect (Lin and Lu, 
1998) depending on whether the mug is pha1macologically active or a pro-dmg. 
Inhibition refers to either enzyme inactivation or competition of substrates for 
a catalytic site. Both responses have the net effect of decreasing the rate of mug 
metabolism and thereby prolonging the half-life of the affected dmg or active 
metabolite and modifying its pha1macodynamic effect (Lin and Lu, 1998). 
In tetms of metabolic m11g interactions, inhibition of enzyme activity seems 
more relevant for study than induction. Inhibition often occurs immediately whereas 
induction usually takes time to bring; about its effect. Inhibition occurs rapidly as 
soon as the inhibitor is present where:as induction takes some time to sta11 (3 to 10 
days) or stop (5 to 12 days) since protein synthesis must first occur and then cease. 
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Inhibition of CYP by d.Iugs, chemicals or natural sources such as herbs can be 
either reversible or ineversible. hTeversible inhibition entails a biotransfmmation of 
the inhibitor, while reversible inhibition can take place directly, without metabolism. 
Reversible inhibition is the most coJIIllllon type of enzyme inhibition and can be 
fmther divided into competitive, non-competitive, uncompetitive, and mixed-type 
inhibitions (Lin and Lu, 1998). 
h"reversible inhibition is also known as mechanism-based inhibition or 
suicidal inhibition. It is characterized by a time-dependent loss of enzyme activity 
and ineversible modification of the enzyme (Flockhrut and Tanus-Santos, 2002). 
Suicide inhibition involves the fmmation of CYP-mediated fmmation of a reactive 
inhibitor. This covalently binds to the protein or heme of the CYP enzyme leading to 
its inactivation. Mechanism-based inhibition is potentially hatmful, since re-
synthesis of the new enzyme is the only approach to restore the enzyme activity, and 
the inhibitory effects of mechanism-based inhibitors remain after the elimination of 
the inhibitor from blood and tissue (Ohyama et a!., 2000). The most impo1tant 
phenomenon of mechanism-based iinhibition is the time-, concentration-, and 
NADPH-dependent enzyme inactivation (Halpe1t, 1995). Classical mechanism-based 
inhibitors used as in vitro tools for selective inhibition of CYPs include furafylline 
(CYP1A2) (Sesardic et al., 1990), paroxetine (CYP2D6) (Blobaum, 2006, 
Hollenberg et al., 2008) and gestodene (CYP3A4) (Guengerich, 1990). 
A clinically impmtant interaction can occur when a d.I11g or herb inhibits a 
dmg-metabolizing enzyme (DME). Reversible inhibition is probably the most 
common for the many documented chug-dmg or d.I11g-herb interactions. Examples 
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include HMG-CoA reductase inhibi1tors (Lin and Lu, 1998). Different kinds of 
enzyme inhibition that can impair dmg metabolism have however been described: 
i) Competitive inhibition: 
This is the most common kind of inhibition but it is unlikely to be the most 
clinically relevant. This competition occurs between the substrate (S) and 
inhibitor (I) for binding at the same position on the active site of the enzyme 
(E). The inhibitor can bind to E but not enzyme-substrate (ES) complex, 
therefore increases the binding efficiency, Km (the inhibitor interferes with 
substrate binding) but does not affect maximum velocity, V max (the inhibitor 
does not hamper the catalysis in ES because it does not bind toES complex). 
ii) Uncompetitive inhibition: 
fu uncompetitive inhibition th~e inhibitor binds only to the enzyme-substrate 
complex, but not to the free enzyme entity. The enzyme-substrate-inhibitor 
complex is nonproductive (Segel 1975; Lin and Lu, 1998). Under this 
mechanism, both V max and Km are decreased. 
iii) Mixed-type inhibition: 
fu practice, with two substrates this type of inhibition displaying elements of 
both competitive and noncompetitive inhibition is the most frequently 
obsetved fmm of inhibition (Madan eta!., 2002). The inhibitor can bind both 
to the free enzyme and to the enzyme-substrate complex but their affinities 
for these two fmms are different. This type interferes with substrate binding 
(increase Km) and hampers catalysis in the ES complex (decrease Vmax). 
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iv) Non-competitive inhibition: 
This is a special case of mixed-type inhibition. The active binding site for the 
substrate and inhibitor is different from each other. The inhibitor has no effect 
on binding of substrate, but the enzyme-substrate-inhibitor complex is 
nonproductive. This type has identical affinities for both E and ES complex, 
therefore it does not change Km (does not affect substrate binding) but it 
decreases v max (inhibitor binding hampers catalysis). 
1.2.8 Characterization of in vitro P'otency of Inhibition 
Inhibitory activity of selective chemical inhibitors of specific CYP enzymes 
can be expressed either as an inhiibition constant (K0 or the 50% inhibitmy 
concentration (IC50) (Beriz and Grarmeman, 1997) . The IC50 is an estimate of the 
concentration of the dmg inhibiting the maximum rate of metabolism of a fixed 
concentration of substrate by 50%. It is a measure of the inhibitory potency 
(http://www.fda.gov/cder/guidance/clin3.pdt). 
The IC50 values are useful when comparing the relative inhibitmy potency of 
different candidate inhibitors. However, an IC50 value is unsuitable to be used in the 
in vitro-in vivo scaling, because it only equals the enzyme inhibition constant (Ki) in 
the case of noncompetitive inhibition (von Moltke et a!., 1998). For any other types 
of inhibition, the IC50 value is generally higher than the respective Ki value, and 
therefore this may result in an underestimation of the in vivo inhibitmy effect of an 
inhibitor. For competitive inhibitors, the IC50 will approximate the Ki only if the 
substrate concentration studied is considerably below the Km (the substrate 
concentration at which the rate of metabolism is half-maximal). 
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In vitro inhibition constant (KD of a dmg or herb for a particular CYP isofmm 
is useful in the investigation of dmg interactions. The Ki is the measure of the affmity 
of the inhibitor for the enzyme. Ki require the study of inhibition at a range of 
concentrations for both the inhibitor and substrate. Ki values, while being 
theoretically dependent on the binding characteristics of the inhibitor, may vaty with 
different substrates (Prakash eta!., 2000). 
1.2.9 Study Hypothesis and Objec1tives 
1.2.9.1 General Objective 
The objective of this study is to generate an in vitro dmg-herbs interaction assay for 
CYP2D6*1 and CYP2D6*10 and to use it to investigate the influence of Eurycoma 
longifolia, Jack on CYP2D6. 
1.2.9.2 Specific Objectives 
The specific objectives of this study are: 
1. to clone and express the recombinant CYP2D6* 1 protein for in vitro 
catalytic study. 
2. to clone and express the recombinant CYP2D6*10 for in vitro catalytic 
study. 
3. to develop a high perfmmance liquid chromatography (HPLC) method for 
the in vitro interaction study of CYP2D6. 
4. to study the kinetic parameters of CYP2D6* 1 and CYP2D6* 10 
5. to study in vitro effect of Eurycoma longifolia, Jack (ELJ) on CYP2D6*1 
and CYP2D6*10 activity. 
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2 MATERIALS AND METHODS 
The overall methodology of this study is shown in Figure 2 .1. This study consists of 
5 main components namely: 
1. Cloning, expression, and characterization of CYP2D6*1 and NADPH-
Cytochrome P450 reductase (CYP-reductase); 
2. Generation, expression, and characterization of CYP2D6*10 and NADPH-
Cytochrome P450 reductase; 
3. Development of HPLC assay Jfor quantification of bufuralol and 1 '-hydroxy-
bufuralol; 
4. In vitro kinetic characterization of CYP2D6*1 and CYP2D6*10 usmg 
bufuralol as substrate; 
5. In vitro interaction study of Eurycoma longifolia, Jack on CYP2D6*1 and 
CYP2D6*10. 
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Figure 2.1 Overall study methodology 
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2.1 Cloning, Expression and Characterization of CYP2D6*1 and NADPH-
Cytochrome P450 Reductase 
Cytochrome P450 2D6 was cloned expressed and characterized together with 
NADPH-Cytochrome P450 reductase using method described below. 
2.1.1 Chemicals, Reagents and Instruments 
Reagents used are listed in Table 2.1 and the instruments are listed in Table 2 .2. 
Table 2.1 Reagent for cloning, exp,ression and characterisation of CYP2D6*1 
an d NADPH C h P450 d - ;ytoc rome re uctase 
No. Reagent Supplier 
1. Cytochrome c Sigma. Poole, UK 
2. 8-aminolevulinic acid (8-ALA) Sigma. Poole, UK 
3. IPTG Sigma. Poole, UK 
4. Lysozyme Sigma. Poole, UK 
5. NADPH Sigma. Poole, UK 
6. Sodium hydrosulfite Sigma. Poole, UK 
7. Resn·iction enzymes New England Biolabs, Beverly, US 
8. PfuTurbo DNA polymerase Stratagene, La Jolla, US 
9. E. coli sn·ain DH5a F ' IQ Stratagene, La Jolla, US 
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Table 2.1 Continued 
No Reagent Supplier 
10. QiAquick® PCR clean kit, Gel extraction kit Qiagen, Crawley, UK 
and mini-preparation kit 
11. P1ima1y and secondary Antibody Chemicon, Temecula, US 
12. TOPO® cloning kit Invitrogen, Califomia, US 
All other reagents and supplies were obtained from standard sources. 
CYP2D6 eDNA of wild type sequence was a gift from Professor Frank J Gonzalez 
from the National Institute of Health, USA. 
Table 2.2 Instrumentation for cloning, expression and characterisation of CYP 
CYP2D6*1 d NADPH C t h P450 d t an - ;y1oc rome re uc ase 
No. Instruments Supplier 
1. Analytical balance Sartorius, Ge1many 
2. Autoclave machine Hirayama Manufacturing Cooperation, Japan. 
Double beam recording 
3. spectrophotometer, model Varian Varian, Inc. , Palo Alto, CA, U.S.A. 
CARY 50 UVMS spectrophotometer 
4. Dry evaporating unit, model18780 Pierce, Rockford, lllinois. 
5. Electrophoresis power supply, EC 250- The1moQuest, E-C Apparatus 90 Division, Holbrook, New York. 
Electrophoresis tank, model Mini and Primo Submarine Gel system, 6. Maxi cell® The1moQuest, E-C Apparatus Division, Holbrook, New York. 
7. Gel documentation system Vilber Lommat, Cedex, France 
8. Gel d1ying kit Promega, Promega Corporation, Madison U.S.A. 
9. HPLC pump, Perkin Elmer series 200 PerkinElmer Life and Analytical Services, U.S.A. 
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